drugset / Trial / NCT02556021

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease

NCT02556021

Phase 3 Completed 324 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the superiority of efficacy of CJ-12420, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4

Timeline

Start
2015-09-22
Primary completion
2016-11-01
Completion
2016-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tegoprazan Other / unclassified 50 mg Oral
Subject Tegoprazan Other / unclassified 100 mg Oral